A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering
A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering
The purpose of this research study is to find out the potential benefits and safety of asenapine (Saphris®) in adults who suffer from the developmental form of stuttering.
It is hypothesized that individuals who are randomly assigned to asenapine will have an improvement in speech as compared to a placebo.
Inclusion Criteria:
Subjects can be enrolled in the study only if they meet all of the following criteria:
5)Subjects will be male or female from the ages of 18-70. 6)Subjects will be of only English speaking.
Exclusion Criteria:
Subjects will be excluded from the study for any of the following reasons: